PRESS RELEASE: Argenta Enters Agreement to Acquire Elanco Animal Health’s Manufacturing Operations in Dundee, Scotland

February 7, 2017, AUCKLAND – Argenta, a New Zealand-owned company dedicated to the provision of services to create, develop and manufacture products for the global animal health industry, has entered an agreement to acquire the manufacturing facility and operations of Elanco Animal Health in Dundee, Scotland.

The acquisition is an important step in Argenta’s EU growth strategy and follows the company’s successful expansion into the United States in 2016, with the purchase of a state-of-the-art pharmaceutical manufacturing plant in Fort Dodge, Iowa.

Elanco and Argenta have also entered into a manufacturing and supply agreement for select Elanco animal health products. The acquisition is anticipated to close at the beginning of Q2 2017. Financial terms of the deal were not disclosed.

Dr. Doug Cleverly, Argenta’s managing director and co-founder, says having a manufacturing presence in the EU will enable the company to better the services it offers clients around the world, and continue its expansion into the European market.

“The Dundee site has a strong focus on quality, as well as excellent capacity and technical capabilities, and will greatly complement our other Argenta facilities. This is critical as all Argenta manufacturing sites are fuelled by the research and development of new animal health products, which keeps the manufacturing portfolio fresh and helps position the Argenta group as a premier, innovation-driven, international Contract Manufacturing Organization (CMO),” he says.

The 80,000-square-foot Dundee facility will be Argenta’s third manufacturing site globally, and the company’s first operations in the EU. It encompasses a manufacturing plant, laboratories and warehouse spaces for the production of a broad range of high-quality animal health products, including non-sterile liquids, suspensions, and gels.

There are 118 Elanco employees at the facility in Dundee. As part of the sale of the site, Elanco will follow the UK consultation process and applicable laws governing the transfer of employees to Argenta.

“We recognise and welcome the additional capabilities that the Scottish workforce will bring to the business, and look forward to a seamless transition and joining the Dundee community over the coming months,” says Dr. Cleverly.

About Argenta
Argenta is a global provider of drug product development, innovative delivery technologies and contract manufacturing services. Dedicated to the animal health industry, Argenta was founded in 2006 in Auckland, New Zealand.  In January 2016, the company opened a new, 145,000-square-feet manufacturing facility in Fort Dodge, Iowa, to complement its New Zealand operations and support continued growth in the United States. The acquisition followed the company’s opening of a drug product research laboratory in the world-renowned science precinct of Kansas University, Lawrence, Kansas in 2012, and the purchase of a New Jersey-based clinical contract research subsidiary, AlcheraBio, in 2008. Today, Argenta employs over 300 staff, both in the United States and New Zealand, and works with 9 of the top 10 global animal health pharmaceutical companies as well as innovative startup firms. The company exports products and services to over 40 countries including United States, Canada, Japan and Europe.

For more information, contact:
Rana Ali
Head of New Business & Client Collaboration
Phone: +64 9 250 3100
– ENDS    –